Patents Assigned to Virginia Commonwealth University Intellectual Property
Foundation
-
Patent number: 11845741Abstract: The present disclosure provides pilocarpine ionic liquid analogs useful in the treatment of ophthalmological disorders such as glaucoma.Type: GrantFiled: September 17, 2021Date of Patent: December 19, 2023Assignee: VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATIONInventors: Juan Wang, Hu Yang
-
Patent number: 11801309Abstract: The present disclosure relates to carbohydrate-functionalized nanoparticles and methods of treating cardiovascular disease (for example, atherosclerosis).Type: GrantFiled: October 27, 2017Date of Patent: October 31, 2023Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: Hu Yang, Shobha Ghosh, Hongliang He, Michael Lancina
-
Patent number: 11369575Abstract: Pharmaceutical particles having an inner portion comprising an agonist of peroxisome proliferator-activated receptor ? (PPAR?) and a biodegradable polymer; and an outer coating comprising an emulsifier which surrounds the inner portion, wherein the agonist may be a fibrate, and the particle contains at least about 5 wt % to about 25 wt % of the agonist, and wherein the particle has a sustained delayed release of the agonist in a range of at least about 1 to 12 months when in an aqueous solution or physiological environment. The pharmaceutical particles may be used, for example, to treat diseases and conditions such as ocular disorders which benefit from PPAR? agonism.Type: GrantFiled: March 18, 2020Date of Patent: June 28, 2022Assignees: The Board of Regents of the University of Oklahoma, Virginia Commonwealth University, Intellectual Property FoundationInventors: Jian-xing Ma, Fangfang Qiu, Qingguo Xu, Tuo Meng
-
Patent number: 11341585Abstract: A hyper-graph sketching framework receives graph data set to generate non-singular reverse cascades in a network to assess influence dynamics therein. A high-quality influence oracle for seed sets uses the resulting sketch data set generated from the non-singular reverse cascades to output estimation of influence.Type: GrantFiled: February 21, 2018Date of Patent: May 24, 2022Assignee: VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATIONInventors: Thang N. Dinh, Hung T. Nguyen
-
Patent number: 10786180Abstract: A system and method for reducing intrafractional motion of a subject The system includes a subject user device, whereby the user device includes an image acquisition device configured to receive location marker information of the subject to provide location marking data of the subject. The system may also include a digital processor configured to: receive the location marking data and determine movement of the subject relative to the location marker information; and communicate feedback of the movement to the subject to help the subject reduce intrafractional motion.Type: GrantFiled: September 29, 2015Date of Patent: September 29, 2020Assignees: University of Virginia Patent Foundation, Virginia Commonwealth University Intellectual Property FoundationInventors: Taeho Kim, Harang Ju, Siyong Kim
-
Patent number: 8586345Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.Type: GrantFiled: March 21, 2011Date of Patent: November 19, 2013Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
-
Patent number: 8211083Abstract: A method, technique and system is disclosed for the delivery of therapeutic agents and/or into the bulk brain tissues and other parts, tissues and organs of the body, including vasculature. A novel form of coaxial catheter provides a means for implanting an outer tube into the brain, then inserting an inner tube into the outer tube and aligning them such that port holes on both of the tubes will overlap and permit a flux of the therapeutic agent to flow into the brain in such a way as to minimize the effects of trapped air, virtually eliminate backflow of the agent, and avoid the potential for additional damage to the brain since only one surgical placement of the outer tube is needed. Similarly, the method, technique system may be utilized to remove fluids or other medium from the brain, tissues, and organs to minimize the effects of escaped air or negative pressure.Type: GrantFiled: April 15, 2010Date of Patent: July 3, 2012Assignees: University of Virginia Patent Foundation, Virginia Commonwealth University Intellectual Property FoundationInventors: William C. Broaddus, Zhi-Jian Chen, George T. Gillies
-
Publication number: 20110280841Abstract: The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more natural materials, one or more synthetic materials, or a combination thereof. The substance can be one or more therapeutic or cosmetic substances or other compounds, molecules, cells, vesicles. The compositions can be used in substance delivery, including drug delivery within an organism by, for example, releasing substances or containing cells that release substances. The compositions can be used for other purposes, such as prostheses or similar implants.Type: ApplicationFiled: January 18, 2011Publication date: November 17, 2011Applicant: Virginia Commonwealth University Intellectual Property FoundationInventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson
-
Publication number: 20110183425Abstract: The application concerns an isolated protein complex comprising polypeptide components: (i) UTP20 HUMAN or a fragment, variant or homologue thereof; (ii) PWP2 HUMAN or a fragment, variant or homologue thereof; (iii) WDR46_HUMAN or a fragment, variant or homologue thereof; (iv) UTP18 HUMAN or a fragment, variant or homologue thereof; (v) MPPIO HUMAN or a fragment, variant or homologue thereof; (vi) WDR3_HUMAN or a fragment, variant or homologue thereof; (vii) TBL3 HUMAN or a fragment, variant or homologue thereof; (viii) WDR36_HUMAN or a fragment, variant or homologue thereof; and (ix) N0C4L HUMAN or a fragment, variant or homologue thereof.Type: ApplicationFiled: June 10, 2009Publication date: July 28, 2011Applicants: BIOCANT- ASSOCIACÃO DE TRANSFERÊNCIA DE TECHNOLOGIA, VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATIONInventors: André Xavier de Carvalho Negräo Valente, Yuan Gao, Gregory A. Buck, Seth Roberts
-
Patent number: 7847120Abstract: The present invention provides novel compositions of allosteric hemoglobin modifiers which are substantially free of impurities, specifically polymeric impurities. In one embodiment, the novel compositions contain an allosteric hemoglobin modifier compound and less than 100 ppm of the polymeric impurities generated during the preparation of this compound. Included in the present invention are novel methods for preparing allosteric hemoglobin modifiers that are substantially free of polymeric impurities. Also included in the present invention are improved methods for the purification of the product formed by the method of this invention. The novel methods of purification comprise extracting the crude composition with a water immiscible or partially immiscible solvent such as methylisobutyl ketone (MIBK) to lower amounts of impurities, specifically polymeric impurities.Type: GrantFiled: April 22, 2005Date of Patent: December 7, 2010Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: Al Quick, Antonio M. Santos, Alexandre J G G Carvalho, Douglas G. Johnson, Jeffrey B. Etter, Christopher Murray
-
Patent number: 7759082Abstract: The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrate to form the tissues and organs.Type: GrantFiled: January 26, 2004Date of Patent: July 20, 2010Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr, Jr.
-
Patent number: 7615373Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.Type: GrantFiled: May 28, 2003Date of Patent: November 10, 2009Assignees: Virginia Commonwealth University Intellectual Property Foundation, Organogenesis, Inc.Inventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
-
Publication number: 20090069623Abstract: The present invention comprises methods and compositions for the treatment or prevention of radiation-induced fibrosis. Methods and compositions for the inhibition of CTGF are disclosed herein. Methods and compositions for treatment of neoplastic disease are disclosed herein. Inhibition of CTGF in humans or animals that have been exposed to ionizing radiation results in treatment or prevention of radiation-induced fibrosis.Type: ApplicationFiled: August 21, 2008Publication date: March 12, 2009Applicant: Virginia Commonwealth University Intellectual Property FoundationInventor: YOUNGMAN OH
-
Publication number: 20080159985Abstract: The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more natural materials, one or more synthetic materials, or a combination thereof. The substance can be one or more therapeutic or cosmetic substances or other compounds, molecules, cells, vesicles. The compositions can be used in substance delivery, including drug delivery within an organism by, for example, releasing substances or containing cells that release substances. The compositions can be used for other purposes, such as prostheses or similar implants.Type: ApplicationFiled: December 21, 2007Publication date: July 3, 2008Applicant: Virginia Commonwealth University Intellectual Property FoundationInventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson
-
Patent number: 7374774Abstract: The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more natural materials, one or more synthetic materials, or a combination thereof. The substance can be one or more therapeutic or cosmetic substances or other compounds, molecules, cells, vesicles. The compositions can be used in substance delivery, including drug delivery within an organism by, for example, releasing substances or containing cells that release substances. The compositions can be used for other purposes, such as prostheses or similar implants.Type: GrantFiled: September 22, 2003Date of Patent: May 20, 2008Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson
-
Publication number: 20080038352Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.Type: ApplicationFiled: August 21, 2007Publication date: February 14, 2008Applicants: Virginia Commonwealth University Intellectual Property Foundation, Nanomatrix, Inc.Inventors: David Simpson, Gary Bowlin, Gary Wnek, Peter Stevens, Marcus Carr, Jamil Matthews, Saravanamoorthy Rajendran
-
Patent number: 6592623Abstract: A muscle implant includes an extracellular matrix, tendon and muscle cells. The extracellular matrix is made of a matrix of electrospun polymer fibers. The tendon is made of extruded collagen fibers and the muscle cells are disposed on the extracellular matrix in such a manner that the combination of components will functionally and structurally act as normal muscle tissue. Cardiac and smooth muscles may be similarly formed without tendons but including the extracellular matrix and muscle cells.Type: GrantFiled: August 31, 1999Date of Patent: July 15, 2003Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: Gary L. Bowlin, Gary Wnek, David G. Simpson, Louis Terracio
-
Patent number: 6277571Abstract: A method of sequential consensus region-directed amplification comprising, (a) amplifying a first segment of at least one target DNA in a DNA mixture, using a first and second oligonucleotide primer, each of which hybridizes to the target DNA, and a nucleic acid polymerase, under conditions in which DNA amplification is achieved, resulting in a first segment of double-stranded DNA; (b) amplifying a second segment of the first segment of double-stranded DNA, using a third and fourth oligonucleotide primer, each of which hybridizes to the first DNA segment, and a nucleic acid polymerase, under conditions in which DNA amplification is achieved, resulting in a second segment of double-stranded DNA.Type: GrantFiled: September 30, 1998Date of Patent: August 21, 2001Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: Helen Fillmore, William Broaddus, George Gillies